Results from an international clinical trial, published June 15 in The Lancet, show that the selective targeted therapy, fruquintinib resulted in a statistically significant improvement in overall survival and progression-free survival.
The European Medicines Agency has validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer.
